These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 16504031

  • 1. Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ, Antonopoulou A, Raftogiannis M, Koutoukas P, Tsaganos T, Tziortzioti V, Panagou C, Adamis T, Giamarellou H.
    BMC Infect Dis; 2006 Feb 21; 6():31. PubMed ID: 16504031
    [Abstract] [Full Text] [Related]

  • 2. Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae.
    Giamarellos-Bourboulis EJ, Tziortzioti V, Koutoukas P, Baziaka F, Raftogiannis M, Antonopoulou A, Adamis T, Sabracos L, Giamarellou H.
    J Antimicrob Chemother; 2006 May 21; 57(5):937-44. PubMed ID: 16549515
    [Abstract] [Full Text] [Related]

  • 3. Immunomodulatory effect of three-day continuous administration of clarithromycin for experimental sepsis due to multidrug-resistant Pseudomonas aeruginosa.
    Baziaka F, Giamarellos-Bourboulis EJ, Raftogiannis M, Adamis T, Tziortzioti V, Sabracos L, Chrisofos M, Koutoukas P, Giamarellou H, Douzinas EE.
    J Chemother; 2008 Feb 21; 20(1):63-8. PubMed ID: 18343746
    [Abstract] [Full Text] [Related]

  • 4. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ, Adamis T, Laoutaris G, Sabracos L, Koussoulas V, Mouktaroudi M, Perrea D, Karayannacos PE, Giamarellou H.
    Antimicrob Agents Chemother; 2004 Jan 21; 48(1):93-9. PubMed ID: 14693524
    [Abstract] [Full Text] [Related]

  • 5. Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli.
    Giamarellos-Bourboulis E, Adamis T, Sabracos L, Raftogiannis M, Baziaka F, Tsaganos T, Koutoukas P, Plachouras D, Karayannacos P, Giamarellou H.
    Scand J Infect Dis; 2005 Jan 21; 37(1):48-54. PubMed ID: 15764190
    [Abstract] [Full Text] [Related]

  • 6. Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli.
    Giamarellos-Bourboulis EJ, Baziaka F, Antonopoulou A, Koutoukas P, Kousoulas V, Sabracos L, Panagou C, Perrea D, Giamarellou H.
    Int J Antimicrob Agents; 2005 Feb 21; 25(2):168-72. PubMed ID: 15664488
    [Abstract] [Full Text] [Related]

  • 7. Esmolol: immunomodulator in pyelonephritis by Pseudomonas aeruginosa.
    Dimopoulos G, Theodorakopoulou M, Armaganidis A, Tzepi IM, Lignos M, Giamarellos-Bourboulis EJ, Tsaganos T.
    J Surg Res; 2015 Sep 21; 198(1):175-84. PubMed ID: 26073350
    [Abstract] [Full Text] [Related]

  • 8. n-6 polyunsaturated fatty acids enhance the activities of ceftazidime and amikacin in experimental sepsis caused by multidrug-resistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ, Mouktaroudi M, Adamis T, Koussoulas V, Baziaka F, Perrea D, Karayannacos PE, Giamarellou H.
    Antimicrob Agents Chemother; 2004 Dec 21; 48(12):4713-7. PubMed ID: 15561848
    [Abstract] [Full Text] [Related]

  • 9. Oleuropein: a novel immunomodulator conferring prolonged survival in experimental sepsis by Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ, Geladopoulos T, Chrisofos M, Koutoukas P, Vassiliadis J, Alexandrou I, Tsaganos T, Sabracos L, Karagianni V, Pelekanou E, Tzepi I, Kranidioti H, Koussoulas V, Giamarellou H.
    Shock; 2006 Oct 21; 26(4):410-6. PubMed ID: 16980890
    [Abstract] [Full Text] [Related]

  • 10. Effect of clarithromycin in experimental empyema by multidrug-resistant Pseudomonas aeruginosa.
    Tsovolou EC, Tzepi IM, Spyridaki A, Tsaganos T, Karagianni V, Menenakos E, Liakou P, Sabracos L, Zografos G, Giamarellos-Bourboulis EJ.
    APMIS; 2014 Jan 21; 122(1):68-75. PubMed ID: 23656439
    [Abstract] [Full Text] [Related]

  • 11. Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study.
    Giamarellos-Bourboulis EJ, Bolanos N, Laoutaris G, Papadakis V, Koussoulas V, Perrea D, Karayannacos PE, Giamarellou H.
    BMC Infect Dis; 2005 Jun 26; 5():51. PubMed ID: 15978135
    [Abstract] [Full Text] [Related]

  • 12. Experimental sepsis using Pseudomonas aeruginosa: the significance of multi-drug resistance.
    Giamarellos-Bourboulis EJ, Koussoulas V, Panagou C, Adamis T, Baziaka F, Skiadas I, Perrea D, Dionyssiou-Asteriou A, Giamarellou H.
    Int J Antimicrob Agents; 2004 Oct 26; 24(4):357-61. PubMed ID: 15380261
    [Abstract] [Full Text] [Related]

  • 13. Early apoptosis of blood monocytes is a determinant of survival in experimental sepsis by multi-drug-resistant Pseudomonas aeruginosa.
    Antonopoulou A, Raftogiannis M, Giamarellos-Bourboulis EJ, Koutoukas P, Sabracos L, Mouktaroudi M, Adamis T, Tzepi I, Giamarellou H, Douzinas EE.
    Clin Exp Immunol; 2007 Jul 26; 149(1):103-8. PubMed ID: 17488299
    [Abstract] [Full Text] [Related]

  • 14. Impact of multidrug resistance on experimental empyema by Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ, Tzepi I, Tsovolou I, Spyridaki A, Tsaganos T, Vaki I, Kotsaki A, Polychronopoulos V.
    Respiration; 2011 Jul 26; 82(1):46-53. PubMed ID: 21525725
    [Abstract] [Full Text] [Related]

  • 15. The significance of oxidant/antioxidant balance for the pathogenesis of experimental sepsis by multidrug-resistant Pseudomonas aeruginosa.
    Koussoulas V, Giamarellos-Bourboulis EJ, Adamis T, Mouktaroudi M, Sabracos L, Perrea D, Giamarellou H, Dionyssiou-Asteriou A.
    Prostaglandins Leukot Essent Fatty Acids; 2005 Jan 26; 72(1):41-7. PubMed ID: 15589398
    [Abstract] [Full Text] [Related]

  • 16. Early cutaneous alterations in experimental sepsis by Pseudomonas aeruginosa.
    Petropoulou H, Giamarellos-Bourboulis EJ, Kavatzas N, Stratigos A, Mouktaroudi M, Adamis T, Baziaka F, Katsambas AD, Stavrianeas NG.
    Dermatology; 2004 Jan 26; 209(2):111-6. PubMed ID: 15316164
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Angiopoietin-2 enhances survival in experimental sepsis induced by multidrug-resistant Pseudomonas aeruginosa.
    Tzepi IM, Giamarellos-Bourboulis EJ, Carrer DP, Tsaganos T, Claus RA, Vaki I, Pelekanou A, Kotsaki A, Tziortzioti V, Topouzis S, Bauer M, Papapetropoulos A.
    J Pharmacol Exp Ther; 2012 Nov 26; 343(2):278-87. PubMed ID: 22859861
    [Abstract] [Full Text] [Related]

  • 20. Early apoptosis of monocytes contributes to the pathogenesis of systemic inflammatory response and of bacterial translocation in an experimental model of multiple trauma.
    Efstathopoulos N, Tsaganos T, Giamarellos-Bourboulis EJ, Kaldis P, Nicolaou V, Papalois A, Koutoukas P, Papachristou G, Giamarellou H.
    Clin Exp Immunol; 2006 Jul 26; 145(1):139-46. PubMed ID: 16792684
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.